NewsRoom Articles - Page 116 of 214

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

MondayApr 11, 2022 2:29 pm

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

New research has found that excessive napping in the daytime for older individuals may indicate a heightened risk of Alzheimer’s disease. The study, which involved a cohort of older individuals, was carried out by researchers at Brigham and Women’s Hospital. The researchers discovered a link between cognitive aging and excessive napping in the daytime, noting that being diagnosed with Alzheimer’s accelerated the increase in daytime napping as an individual aged while excessive napping during the daytime forecasted an elevated future risk of Alzheimer’s. The study’s findings were reported in “Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.” Peng Li,…

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

MondayApr 11, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal…

FridayApr 08, 2022 2:46 pm

Gun Violence Survivors at Higher Risk of Being Diagnosed with Mental Health Issues

Estimates show that in the United States approximately 85,000 individuals survive gun injuries, while another 40,000 are killed by guns annually. New research has found that the consequences of gun violence extend far beyond the damage caused by the injury. Long-term repercussions include substance-use disorders, worsened mental health and increase in healthcare costs incurred for survivors as well as increased mental health conditions for their significant others and children. The study was carried out by researchers at Harvard Medical School. Its findings were reported in the “Annals of Internal Medicine.” This is the first quasiexperimental, large-scale study to look into…

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

ThursdayApr 07, 2022 2:43 pm

Study Finds That Mild Covid Infections May Cause Inflammation in Cells Months Later

Researchers have found evidence that the human immune system is more prone to inflammation after an individual suffers from a mild case of the coronavirus. Inflammation occurs as an individual’s body responds to infection from germs. However, in some coronavirus-infection cases, the immune response causes damage throughout an individual’s body. The study was carried out by researchers at the Karolinska Institute in Sweden, as well as Germany’s Technical University of Munich and the Helmholtz Center Munich. The researchers’ objective was to learn more about the changes to the immune system that may occur in milder coronavirus-infection cases. For their research,…

WednesdayApr 06, 2022 2:46 pm

Study Finds That Exercise May Reduce Symptoms of Depression

New studies have found that exercising for 30 minutes may boost the benefits of therapy and decrease symptoms of depression for at least an hour and 15 minutes post workout. The studies were carried out by Iowa State University researchers, led by Professor Jacob Myer, who was also the lead author. The objective of the research was to find out how exercising influenced the symptoms of depression. For their first study, the researchers recruited 30 adults who experienced major depressive episodes. Each participant was required to fill out surveys, which included the scales used to measure a number of cognitive…

WednesdayApr 06, 2022 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions,…

TuesdayApr 05, 2022 2:48 pm

Researchers Explain the Link Between Diabetes, Hypertension

A new study conducted by a team of researchers from the Universities of Bristol and Auckland has discovered why most patients with hypertension also suffer from diabetes. Hypertension is also referred to as high blood pressure and is known to increase an individual’s risk of stroke and heart disease, among other indications. It can also cause severe health complications, sometimes leading to death. On the other hand, diabetes is a chronic health condition that develops when an individual’s body can’t effectively use the insulin it produces or when their pancreas doesn’t produce enough insulin. The condition, which is sometimes referred…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

Study Links Excessive Napping to Increased Risk of Developing Alzheimer’s

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

Gun Violence Survivors at Higher Risk of Being Diagnosed with Mental Health Issues

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Study Finds That Mild Covid Infections May Cause Inflammation in Cells Months Later

Study Finds That Exercise May Reduce Symptoms of Depression

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

Researchers Explain the Link Between Diabetes, Hypertension

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search